Proactiveinvestors USA & Canada Proactiveinvestors Proactiveinvestors USA & Canada Proactiveinvestors RSS feed en Thu, 20 Jun 2019 19:07:35 -0400 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[News - Trade rhetoric uncovers new interest in rare earths miners ]]> As the trade rhetoric heated up between the US and China this week, one sector stands to potentially benefit from all the political posturing: rare earths miners.

Rare earths, particularly rare earths magnets, are likely to be in increasing demand as the world moves away from traditional sources of energy and toward renewables. Rare earths are used in wind turbines and lithium ion batteries, in consumer electronics and in air conditioning units.

That makes them -- and the companies that dig them up -- crucial both to power generation and to transport and, in the context of the pledge of Germany, for example, to cut all coal power generation by 2038, highly strategic.

WATCH: CEO of Medallion Resources sees trade dispute between China and US as an opportunity

Some forecasters were expecting the Chinese to become net importers of rare earths in 2020, as the country moves to clean up or shut down polluting mines, and domestic demand rises.

Despite of the name, rare earths aren’t actually that rare. Neodymium and praseodymium, two of the most widely used rare earths, rank 28 and 40th, respectively, in terms of abundance among elements in the earth’s crust, ahead of tin, uranium, tantalum, molybdenum and silver.

China accounts for between 70% and 80% of global rare earths supply and is a key global price setter.

Conversely, the US has no current domestic rare earth production, and recently passed the McCain Act, which further complicates the picture by banning the import of certain types of rare earth magnets from countries it wishes to steer clear of, most notably Iran, but also North Korea and China.

What to watch

With that in mind, which global rare earths miners should be on your radar as these two economic giants dig in their heels?

Shares in Arafura Resources Ltd (ASX:ARU) jumped by more than 15% Thursday on the Australian Securities exchange, as Chinese officials explicitly referenced rare earths. The company is at an advanced stage with its Nolans REO (rare earth oxide) project in the Northern Territory, having completed a DFS (definite feasibility study). The project is effectively at the starting blocks pending an expected spike in the NdPr (neodymium and praseodymium) price.

Shares in Mkango Resources Ltd (LON:MKA), which has a rare earths project under development in Malawi, jumped 20% in midday trading in Toronto. The market had been somewhat more cautious in bidding for Mkango, because it isn’t in production yet. But more speculative-minded investors might reckon that that makes the upside still more attractive.

READ: Arafura Resources’ rare earth project has significant catalysts in the current year: Patersons

Lynas Corp’s (ASX:LYC) is already well established as arguable the most significant rare earths producer outside of China, with mines in Australia and Malaysia. Its share price had already strengthened considerably before the latest Chinese sabre rattling in response to a A$1.5bn offer tabled by giant Australian conglomerate Wesfarmers (ASX:WES). Its stock jumped by more than 15% in Australia on Wednesday before pulling back today.

Medallion Resources Ltd (CVE:MDL) is focused on extracting rare earths from monazite, a byproduct mineral of heavy mineral sands mining. Unlike traditional rare earths mining, which can be laborious and expensive, Medallion is pioneering a process that extracts what is known as magnet metals, more specifically neodymium and praseodymium (NdPr), from monazite. Its shares were in retreat in afternoon trading.

Other names for investors to consider include Peak Resources, Alkane, Molycorp and Hastings.

Why rare earths matter

Despite a relatively weak pricing environment, all these names are moving forward with established projects.

If a crunch does come, investors may move on these companies first. After that, blue sky projects will come into play, which presents a much longer proposition.

--Alastair Ford and Tharun George contributed to this report

Thu, 30 May 2019 14:36:00 -0400
<![CDATA[News - FDA to hold its first public hearing Friday on regulating CBD ]]> CBD-infused products such as lotions, capsules and oils are already widely available in major chain stores such as CVS and online. And the non-intoxicating cannabis component, cannabidiol, is starting to turn up in food and beverages as other companies make plans to get on the CBD bandwagon.

Companies that manufacture and sell CBD products typically market them as a safe and natural way to combat anxiety, inflammation and insomnia. Other vendors, however, are pushing the marketing envelope by touting CBD as some miracle-cure-all for Alzheimer’s disease, cancer and ADHD in the face of nonexistent or nebulous research.

But now this unregulated Wild West of sorts in the North American CBD industry, estimated to be worth $16 billion by 2025, could be coming to an end, as the US Food and Drug Administration will hold its first public hearing this Friday on how it should regulate cannabis and CBD.

CBD industry needs uniform product standards

Regulating the CBD free-for-all, which will come soon via the FDA or Congress, could be a good thing for a fast-growing industry that needs uniform product standards and rules of operation so players can market effectively and legally as well as communicate properly with investors, experts say.

“Regulation enables growth in every successful industry, and we have a once-in-a-lifetime opportunity to create a multibillion-dollar market that meets consumer needs,” said Josh Epstein, chief executive of Socati, an Oregon-based processor of broad spectrum hemp extracts.

But guidance is needed on critical matters, especially when it comes to establishing a credible verification process to guarantee product purity, quality manufacturing, and labeling transparency, he said.

“Without that, a race to the bottom is inevitable as irreputable companies continue to pop up, and consumers face harm from products that contain unknown quantities of cannabinoids or products contaminated with pesticides or heavy metals,” Epstein said.

FDA focusing on CBD as a food and beverage ingredient

The FDA is not expected to issue any decisions during what is a information-gathering process, but the agency will have a strong focus on how CBD is marketed and how much CBD should be added to food and drinks (if at all).

The regulator has been under pressure to create a regulatory framework for CBD -- which took a new urgency when Congress make hemp legal in December under the Farm Bill.

The vast majority of CBD is extracted from hemp, which is a cannabis plant that has trace amounts of THC (0.3% or less). THC, or tetrahydrocannabinol, is the psychoactive compound that gets people “high.”

CBD was not legalized in the Farm Bill, but rather it was moved under the purview of the FDA, which immediately said companies cannot add it to food or beverages. 

FDA already issuing warnings over 'snake oil' claims in CBD marketing

The FDA also has sent warning letters to a few CBD companies that have made unsubstantiated health claims for serious ailments. In addition, the agency has expressed concern that allowing CBD in food could dampen incentives for drug makers to conduct research into CBD’s health benefits.

In announcing the hearing, then-FDA Commissioner Scott Gottlieb said in a statement that there are “open questions about whether some threshold level of CBD could be allowed in foods without undermining the drug approval process or diminishing commercial incentives for further clinical study of the relevant drug substance.”

Industry experts predict that when eventual regulations are adopted, they’ll probably allow lower for concentrations of CBD as a food additive and higher concentrations as an approved drug.

Contact the author:

Follow him on Twitter @PatrickMGraham

Thu, 30 May 2019 11:13:00 -0400
<![CDATA[News - Canadian cannabis workers wouldn’t be denied entry into the US under new House bill ]]> Canadian cannabis workers wouldn’t be denied entry into the US under new legislation introduced this week in Congress.

Called the Maintaining Appropriate Protections for Legal Entry, or MAPLE Act, the bill would would ensure that non-US citizens are not penalized under federal law for working in the cannabis sector of a foreign country, among other jurisdictions. The bill would create exceptions in U.S. immigration code. 

Rep. Earl Blumenauer (D-Oregon) filed the bill on Tuesday, according to his press secretary. Oregon is one of 11 US states in which cannabis is legal for medical and recreational purposes. 

The congressman submitted an earlier version of the bill in December, about two months after Canada started to allow legal cannabis sales.

READ: Canadian cannabis workers could face a lifetime border ban but it’s not likely

The bill’s creation also comes after reports of Canadian cannabis executives and investors traveling on business and to conferences being barred from entering the US.

Currently, the US Customs and Border Protection, or CBP, maintains it would ban Canadian citizens visiting the US if they admit to working or even investing in the cannabis sector, which has been fully legal in Canada for adult recreational use since last October. 

The CBP deems any investment, even in medical cannabis, a crime because cannabis, like heroin, remains a Schedule I drug in the US and thus illegal at the federal level.

For example, according to Bloomberg Law, the CBP had questioned a Canadian investor in the cannabis industry who was traveling to Las Vegas to attend a marijuana industry conference and tour a new cannabis facility. The CBP then banned the investor for life from entering the US.

The CBP declined to comment on Rep. Blumenauer’s bill. 

Under the bill, visitors to the US wouldn’t be denied entry for engaging in the “trafficking, sale, or distribution of marijuana if the conduct was lawful or subsequently made lawful in the State, Indian Tribe, or foreign country in which it occurred.”

Contact the author:

Follow him on Twitter @PatrickMGraham

Thu, 16 May 2019 14:38:00 -0400
<![CDATA[News - Canada adds 107,000 jobs during April, smashing estimates ]]> New data released from Statistics Canada this morning showed employment rose by 107,000 during the month of April, smashing estimates.

The unemployment rate fell to 5.7%.

Analyst expectations for April’s figures were mixed, but the upper range of gains was put around 20,000 new jobs.

READ: Canadian job figures down in March after strong quarterly growth

The total number of jobs in Canada came in at 19 million, up 116,000 in the first quarter of 2019 and 332,000 on a year-over-year basis.

Jobs in the natural resources sector, which is a major employer of Canadians, were down another 2,000 during the month compared with March's figures. The sector has gained nearly 8,000 new jobs since March 2018.

Job growth in 2019 have helped boost investor confidence in the Canadian dollar, counteracting other data that points to a slowdown in Canada’s economy.

In recent months, however, job figures have been more volatile, leading investors to prepare for more disappointing data.

Contact Angela at

Follow her on Twitter @AHarmantas

Fri, 10 May 2019 08:33:00 -0400
<![CDATA[News - Medicinal cannabis: UK remains behind the curve despite new legislation ]]> Medicinal cannabis was legalised in the UK for the first time in November 2018 but many NHS doctors still are reluctant to prescribe it to patients.

Campaign groups have claimed that the current system in place means patients who can afford private health have gained greater access to medicinal marijuana since the rules were changed but many of those relying on the NHS are being turned away.

What are the rules?

The revised rules mean specialist doctors can prescribe medicinal cannabis, including products containing low levels of tetrahydrocannabinol (THC) – the psychoactive cannabinoid that gets a user “high”.

The regulatory change followed an outcry over the cases of two children who were denied access to cannabis oil to control their severe epilepsy.

The parents of Alfie Dingley and Billy Caldwell said their seizures stopped after taking a THC-based medication.

That sparked a review by England's Chief Medical Officer, Prof Dame Sally Davies, who concluded there were some clinical benefits to medicinal cannabis.

However, the rules surrounding THC remain strict.

Specialist doctors can only prescribe cannabis products containing THC in extreme circumstances such as cases of children with severe forms of epilepsy, adults with vomiting caused by chemotherapy and adults with muscle stiffness caused by multiple sclerosis.

What is the difference between THC and CBD?

Cannabis is made up of 483 compounds, the most dominant of which are cannabinoids known as THC and cannabidiol (CBD).

The medicinal cannabis prescribed by specialist doctors will contain CBD and low levels of THC.

THC produces the high people feel when smoking or ingesting marijuana.

Most of the cannabis being sold illegally in the UK contains a higher percentage of THC than some other types of the drug.

Cannabis with high levels of THC has been linked to psychiatric issues, particularly among adolescents who take large amounts.

CBD, on the other hand, is nonpsychoactive and can be well tolerated.

For this reason, the substance is not restricted in the UK and is widely available at retailers as an oil, spray or food supplement.

CBD products can be sold without a licence so long as claims are not made about their medical benefits.

The products available at stores contain a low percentage of CBD and are mixed with other substances.

For instance, CBD oil is mixed with a carrier oil, often hemp seed or coconut.  

But it has been argued that increasing the amount of CBD used in products would be pointless.

The entourage effect

Geremy Thomas, chief executive of the UK’s first medicinal cannabis investment vehicle, Sativa Investments, said it’s the “entourage effect” of all the compounds in a cannabis plant working together that help treat medical conditions. 

Pointing to the cases of Alfie Dingley and Billy Caldwell, Thomas said if they were given a product containing pure CBD it has been doubted their seizures would stop.

“It’s the fact that there was a small amount of THC present, which really activated the medicinal effect,” he said.

Scientists are still researching CBD and THC but the combination of the two has been used to help treat seizures, inflammation, muscle spasticity and glaucoma.

Thomas said the ideal percentages of THC and CBD used in medicinal cannabis depends on ailment being treated and more research needs to be done into the effect of different combinations.

Since medicinal cannabis is mostly unlicensed, doctors will only prescribe it for needs that can't be met by licensed medicines.

Sativex spray, which is a 50-50 combination of THC and CBD, has been approved for use in the Britain by the Medicines and Healthcare products Regulatory Agency as a treatment for multiple sclerosis.

However, the National Institute for Health and Care Excellence (NICE), which issues guidance to NHS doctors, in 2014 recommended against prescribing Sativex because it was not cost-effective.

Sativex costs about £140 per 10ml bottle, which contains 90 doses.

Will the UK ease up the rules?

Health secretary, Matt Hancock, has admitted that the current system for prescribing medicinal cannabis is not working after Emma Appleby had a supply of medical cannabis for her severely epileptic nine-year-old daughter, Teagan, confiscated while trying to enter the UK in early April. 

The government has asked NICE to develop additional clinical guidelines on cannabis-based medicinal products, which are due to be released in October.

With attitudes changing on medicinal cannabis, Thomas expects the government will eventually relax the rules on the drug.

“Absolutely, I think the door is open, a very small distance, and it will inevitably open wider and wider,” he said.

“At the moment regulators are under top-down pressure from the politicians and are resisting that pressure, or struggling to cope with that pressure, but they are working hard to deliver for UK patients in accessing medical cannabis.”

“And I do think that the UK medicinal cannabis market will end up being the largest in Europe, which in turn will significantly compete with, if not dwarf, what we’ve seen in North America.”

Thomas said there is a big opportunity in the UK given that it has a large aging population, which he sees as a “positive indicator to medical cannabis uptake”.

Will the UK ever legalise recreational cannabis?

The UK remains well behind the curve compared to North America. Canada legalised recreational cannabis in October 2018 and has allowed the use of medicinal cannabis since 2011.

While cannabis remains illegal at a federal level in the US, recreational marijuana is now legal in 10 states and medical marijuana is legal in 33.

Thomas sees the UK following suit on recreational cannabis eventually but not any time soon.

“When I was first interviewed after setting up Sativa Investments in 2017 I was asked when I thought the regulations would change to approve medicinal cannabis in the UK and I said two to three years and it turned out to be four to five months,” he said.

“If you ask me now about recreational use in the UK, I would suggest it was a long way down the road but who knows it does make sense."

Thomas said there is a case for legalising recreational cannabis as it could mean people stop buying high strength cannabis illegally from the streets and start using regulated products with lower levels of THC.

“(Recreational use) is not a position Sativa Investments takes – it’s a medicinal cannabis company – but if I was to put money on it, I should think that we would follow the rest of the countries around the world.”

New research underway

Sativa Investments has teamed up with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases.

READ: Sativa Investments teams up with King's College London to research cannabinoids for medicinal use

Under the agreement, Sativa Investments will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids.

Mon, 22 Apr 2019 10:00:00 -0400
<![CDATA[Media files - Copper 'a clear investor favourite' in the run-up to Mines and Money New York ]]> Mon, 15 Apr 2019 12:47:00 -0400 <![CDATA[Media files - Heavy Metals takes a deep dive with a look at Zinc ]]> Mon, 15 Apr 2019 10:02:00 -0400 <![CDATA[News - Canadian job figures down in March after strong quarterly growth ]]> New data released from Statistics Canada this morning showed a decrease of 7,200 jobs in March but a steady unemployment rate of 5.8%.

The total number of jobs in Canada came in at around 19 million, up 116,000 in the first quarter of 2019 and 332,000 on a year-over-year basis.

Jobs in the natural resources sector, which is a major employer of Canadians, decreased by 5,000 during the month compared with February’s figures. The sector had gained nearly 8,000 new jobs since March 2018.

Overall, financial jobs, including insurance, real estate and leasing, saw the biggest increase with 13,000 new jobs added. On the flipside, employment declined in health care and social assistance, with a loss of 20,000 positions.

Among Canada's provinces, employment increased in Saskatchewan, New Brunswick and Prince Edward Island, while it was little changed in the remaining provinces.

Expectations higher for the month

The newly-released figures were below analysts' expectations, who had predicted little change this month in both employment numbers and the unemployment rate.

Jobs growth in 2019 has helped boost investor confidence in the Canadian dollar, counteracting other data that point to a slowdown in Canada’s economy.

In recent months, however, job figures have been more volatile, leading investors to prepare for more disappointing data this month.

The Bank of Canada will take these new figures into account as it considers whether to cut interest rates this year.

--Updated with provincial and industry data--

Contact Angela at

Follow her on Twitter @AHarmantas

Fri, 05 Apr 2019 08:44:00 -0400
<![CDATA[Media files - Bioxytran Inc in advanced talks to take its two exciting assets into the clinic ]]> Tue, 02 Apr 2019 13:34:00 -0400 <![CDATA[Media files - Proactive Investors take a closer look at the Lithium market and where it's going ]]> Mon, 01 Apr 2019 16:51:00 -0400 <![CDATA[Media files - Proactive Investors looks at the Winners and Losers in Cannabis with Buds and Duds ]]> Fri, 29 Mar 2019 15:01:00 -0400 <![CDATA[Media files - Tightening supply bodes well for new Vanadium projects ]]> Wed, 27 Mar 2019 13:17:00 -0400 <![CDATA[Media files - Heavy Metals gets stoned on diamonds ]]> Mon, 25 Mar 2019 12:49:00 -0400 <![CDATA[News - New Jersey cancels vote on bill legalizing marijuana ]]> New Jersey state legislative leadership nixed a vote on a bill that would've legalized recreational marijuana in the Garden State.

Gov. Phil Murphy, who campaigned on legalization, spent the past week reaching out to state senators, reported, but couldn't get the legislation over the finish line. Another vote is unlikely to be scheduled prior to the November elections.

The move pushes back the timeline for adult-use marijuana, an industry that would need about a year to get up and running after legalization passes.

The bill included a six-month buffer for regulations to be drawn up, and medical marijuana sellers would need approval before expanding to the public at large. 

Currently, there are six marijuana dispensaries in the state, per, which could double before sales begin. Those dispensaries would need to prove the have enough capacity to sell to all their patients before selling to the public. 

Contact Andrew Kessel at

Follow him on Twitter @andrew_kessel

Mon, 25 Mar 2019 12:11:00 -0400
<![CDATA[Media files - 'It's a brilliant time to have a tungsten project' - Roskill's Jessica Roberts ]]> Mon, 25 Mar 2019 10:52:00 -0400 <![CDATA[Media files - Salt prices remain healthy despite record levels of trading ]]> Fri, 22 Mar 2019 13:17:00 -0400 <![CDATA[Media files - Heavy Metals takes a look at an emerging gold market: Japan ]]> Tue, 19 Mar 2019 16:27:00 -0400 <![CDATA[News - Brexit process remains unclear as Parliament votes against a no-deal exit ]]> How Britain will exit the European remained unclear Wednesday as Parliament voted to reject a no-deal Brexit.

Members of Parliament voted 321 in favour to 278 against on a government motion that they do not want to leave without a deal - a move that has been dubbed a "cliff-edge" departure.

Before that, they voted 312 to 308 on an amendment to reject leaving the bloc without an agreement under any circumstances.

It was one of a series of votes on Brexit and means lawmakers can now get a vote (planned for Thursday) on extending the process, meaning the March 29 date touted for the past two years is no more.

In addition, MPs voted 374 in favor to 164 against to reject a plan to delay the exit until May 22, so there could be a "managed no deal"

Wed, 13 Mar 2019 15:58:00 -0400
<![CDATA[News - Quadriga cryptocurrency goes missing after founder's death, investigators reveal ]]> The cryptocurrency wallets of a man who died without giving anyone else the password, have been found empty by the firm appointed to secure access and recover clients' holdings. 

Gerald Cotten, the founder of the Canadian cryptocurrency exchange, passed away in India in December last year and was the only person who knew the password to unlock the digital wallets held on his laptop.

READ: Crypto exchange left skint after only password holder dies

Auditor Ernst & Young - appointed to wind up QuadrigaCX - had expected to find the wallets full of C$180mln in crypto-cash deposited by 115,000 customers.

But once E&Y investigators gained access, they discovered the wallets had been cleaned out months before Cotton died, according to the BBC. 

Most of the cryptocurrency that customers deposited with the exchange was meant to be kept in ‘cold storage’, an offline environment designed to protect stored cryptocurrencies from internet hackers.

E&Y said it did not know what happened to the digital cash they had expected to find in the storage.

However, the auditor found evidence Cotten had 14 other user accounts "created outside the normal process" that may have been used to trade on the QuadrigaCX exchange.

E&Y is now looking into the trading that was carried out through these other accounts to find out if it can trace the crypto-cash that passed through them.

Tue, 05 Mar 2019 14:49:00 -0500
<![CDATA[Media files - Proactive Investors Heavy Metals shines bright with a look at Copper ]]> Mon, 04 Mar 2019 11:38:00 -0500 <![CDATA[Media files - Proactive's Heavy Metals takes a deep dive on zeolite ]]> Mon, 25 Feb 2019 07:00:00 -0500 <![CDATA[Media files - Cobalt has had a stormy year, does the blue metal have blue skies ahead? ]]> Thu, 21 Feb 2019 11:47:00 -0500 <![CDATA[Media files - Proactive Investors looks at the Buds and Duds of the Cannabis world ]]> Tue, 12 Feb 2019 10:32:00 -0500 <![CDATA[Media files - Proactive's Heavy Metals takes a closer look at graphite ]]> Mon, 11 Feb 2019 13:37:00 -0500 <![CDATA[Media files - Proactive Investors takes a look at the Buds and Duds of the Cannabis World ]]> Fri, 08 Feb 2019 13:32:00 -0500 <![CDATA[Media files - Is the price of Gold on the rise? Proactive's Heavy Metals takes a deep dive ]]> Mon, 04 Feb 2019 16:01:00 -0500 <![CDATA[News - Amid the current global uncertainty, how bearish should we be on copper? ]]> What should we make of the current price of the bellwether metal, copper?

It’s been on a significant downtrend lately, as a succession of poor economic numbers out of China have spooked markets and led to speculation that demand could slow.

In part, this is because of the economic warfare between China and the USA. As a headline grabber, Apple Inc’s (NASDAQ:AAPL) recent warning on Chinese revenues was second to none, but underlying the woes of the world’s ex-biggest tech company are the deeper woes of China.

Exports are slowing, consumer demand is slowing, there are fears about bursting credit bubbles, and on top of all that, in spite of all the progress in recent years, it’s still an opaque country that’s hard for market participants really to read.

Will President Xi crack under this tariffs pressure and sign up to a trade deal that’s advantageous to the US and which will allow Mr Trump to claim victory? Or will he double down, reckoning that the country that’s endured the Great Leap Forward and the Cultural Revolution is more than capable of weathering the effects of a mere tariff war?

At this stage, the uncertainty is almost more problematic than the eventual outcome, as markets don’t know which way to look.

There seems a very real possibility that as a result of the tariff war, and ongoing economic weakness in Germany and Japan, that global growth will slow markedly this year. It’s been enough to make the Federal Reserve put the brakes on its monetary tightening, even thought the US itself is still booming, and its been enough to spook stock markets world wide.

Commodities too, with the honourable exception of gold, have taken a hit.

The copper price has fallen by more than US$1,000 per tonne since the optimism peaked in the spring of 2018, and current sentiment would have it fall further. On the other hand, looking back slightly further, the price is still above the 2016 troughs. So, mixed signals then.

Broker Liberum talks of “difficult dynamics” for the next six months, while conceding that copper remains the favoured commodity for most major miners. That being so, and with the balance sheets of the majors all in good shape at the moment, there may be an opportunity for buying the likes of Antofagasta (LON:ANTO) or Glencore (LON:GLEN) on further dips.

However, Liberum reckons greater value is to be found amongst the more significant of the companies with large projects moving through the development stages.

On this thinking Liberum highlights Asiamet (LON:ARS) and Solgold (LON:SOLG) as offering the best value, while it recommends steering clear of KAZ Minerals (LON:KAZ), on the basis of Russian risk.

Another company worth considering is Kincora Copper (CVE:KCC), which is at an earlier stage, but which may well be sitting on most of the useful ground in the next major district play to emerge in copper mining: Mongolia.

Liberum reckons most of the speculative positions that were taken up in copper in 2018 have now washed out through the system. However, in terms of pricing, negotiations between the US and China will continue to be crucial.

“We believe the issues around industrial output can and probably will be solved, however the controls on intellectual property transfers will be far greater hurdles and we do not expect to see a solution in the next six months,” the broker said.



Wed, 16 Jan 2019 10:36:00 -0500
<![CDATA[News - Canada's job market grew by just 0.9% last year, while unemployment remains at record low ]]> Canada's monthly jobs report out today showed the economy was fairly robust with employment holding steady last month (December) and the jobless rate unchanged.

Those in jobs in Canada totalled 18.8 million in December, up 9,300 jobs on the previous month, while the unemployment rate was 5.6% - unchanged on the month and the lowest on record.

That was better than expected as some economists had expected the unemployment rate in Canada would tick up to 5.7% from 5.6%.

The job creation number was slightly lower than the figure of 10,000 that economists had expected.

Wage growth, however, was disappointing, with growth for December at 1.49% which is well below inflation.

Jobless rate fell 0.2 percentage points in 2018 to 5.6%, the lowest level since comparable data became available in 1976. Canada added 163,300 net new jobs last year and saw an increase in full-time employment, though the pace of growth was slower than previous years.

— CBC News Alerts (@CBCAlerts) 4 January 2019

In the 12 months to December, employment increased by 163,000  jobs, or an increase of 0.9%, driven by gains in full-time work. Meanwhile, over the same period, total hours worked rose 0.9%.

However, the pace of employment growth was slower compared with previous years. In 2017, it saw 2.3% of growth and in 2016, it was 1.2%.

Breaking the figures down by industries, last month, 24,000 more people were employed in manufacturing, with the bulk of the increase in Ontario and Alberta.

Employment in transportation and warehousing rose by 15,000 jobs, continuing an upward trend that began in early 2016. The bulk of the increase in December was in Ontario.

There were also job gains in health care and social assistance, with 11,000 more people working in the industry last month. Again, most of the gains were in Ontario - the country’s most populous province accounting for 28% of the overall population.

Conversely, 26,000 fewer people were working in wholesale and retail trade, most notably in Ontario.

Employment in public administration was down 17,000 in December, with declines in Ontario, Alberta and Nova Scotia.

Analysts at banking giant ING noted that Canadian wage growth failed to pick up in December, which coupled with other global risk factors, meant the Bank of Canada is likely to side with caution and push back the next rate hike until March.

"A rate hike later in the first quarter (in March) still could be on the cards, unless the risk environment worsens further," it said."This would allow policymakers a bit more time to evaluate the impact of lower energy prices on growth, as well as whether business investment and wage growth have begun to perform more strongly."

Contact Giles at

Follow him on Twitter at @Gile74

Fri, 04 Jan 2019 08:59:00 -0500
<![CDATA[News - US mining industry added 3,700 jobs in December while oil and gas extraction gained 300 positions ]]> The US mining industry increased employment by 3,700 jobs to 710,700 positions in December, the Labor Department reported Friday.

The Bureau of Labor Statistics said that the oil and gas extraction sector increased employment by 300 jobs to 154,700 positions.

READ: US mining jobs still buoyant as non-farm payroll figure comes in below expectations

The mining industry excluding oil and gas exploration increased its employment by 900 to 192,100.

The BLS said that coal mining jobs rose by 600 to 53,900 and that nonmetallic mineral mining and quarrying grew by 400 positions to 99,800. Metal ore mining, meanwhile, saw a decrease of 100 jobs to 38,400.

Support activities for mining saw an increase of 2,500 to 363,900.

"It is highly competitive to find and keep experienced employees," Gold Resource Corp (NYSEAMERICAN:GORO) CEO Jason Reid said in an e-mailed response to questions. "A large percentage of the industry is approaching retirement age, with fewer people entering the industry to replace them."

The Dow Jones Industrial Average rose 600 points as total non-farm payroll employment increased by 312,000 in December, well above consensus estimates of 177,000 jobs created.

The unemployment rate, however, increased to 3.9%, up from 3.7% in November.

–This story has been updated to add mining sector data and executive comment–

Contact Dennis Fitzgerald at

Fri, 04 Jan 2019 08:47:00 -0500
<![CDATA[News - CryptoCann™ Report: Marijuana cigar sold for $11,000; Bitcoin in the red at end of 2018 ]]> All but one of the top 20 cryptocurrencies by market cap are in the red on the cusp of the New Year, as data from Coin360 shows, a report by Cointelegraph said.

Losses among the larger cryptocurriences are tempered, with most losing 2% to 3%, and losses capped at 6%

Bitcoin (BTC) has seen a mild loss of about 2%, per the report, and is trading near $3,816. The closing week of 2018 has been volatile for the currency, with Bitcoin surging past $4,200 on December 24, and then sliding close to the $3,600 mark December 28. The coin has mostly traded sideways in the $3,800 to $4,000 range, the report added.

READ: Bitcoin price hits two-week high past $4,000 ahead of the holidays

A survey by Chinese blockchain news site PANews showed that 63% of 4,200 people think cryptocurrencies like Bitcoin are unnecessary as a payment system. However, 40% would consider investing in cryptos, a report by CCN said.

About 14% of the people surveyed had invested in cryptocurrencies already. The majority of the people who were interested or invested were born after 1990, the report said.

The majority of people who are invested in cryptocurrency in China’s investment community were born in the 1990s. Of the 372 people who indicated that they understood blockchain well, the majority were born after 1995, while the second-place group was born after 1990, the report said.

The Cann Report

A Las Vegas marijuana dispensary reportedly sold the country's most expensive pot product to date Friday night, an $11,000 marijuana-packed cigar, a report by Newsweek said.

The 24-gram, weed-stuffed cannagar was sold to several Los Angeles residents including 36-year-old Brandon Hawkins, who paid with six stacks of rubber banded $20 bills, per the report.

Hawkins told the Las Vegas Sun newspaper he was inspired to smoke the record five-figure pot product on New Year's Eve after a similar product was sold in Seattle last June for $10,000.

The cannagar includes a hemp and 24-karat gold leaf-coated exterior made by the Washington state-based company Leira.

READ: 1933 Industries ends 2018 on high note as revenue climbs

The year 2018 was a 12-month champagne toast for the legal marijuana industry as the global market exploded and cannabis pushed its way further into the financial and cultural mainstream, a report by the Journal Star said.

California became the largest legal US marketplace, Utah and Oklahoma embraced medical marijuana, and the US East Coast got its first commercial pot shops. Canada ushered in broad legalization and Mexico’s Supreme Court set the stage for that country to follow.

US regulators approved the first marijuana-based pharmaceutical to treat kids with a form of epilepsy, and billions of investment dollars poured into cannabis companies. Even main street brands like The Coca-Cola Company (NYSE:KO) said it was considering joining the party.


Contact Rene Pastor at

Mon, 31 Dec 2018 11:05:00 -0500
<![CDATA[News - Bitcoin price hits two-week high past $4,000 ahead of the holidays ]]> Bitcoin, the digital asset synonymous with cryptocurrency, has broken out past the $4,000 mark for the first time in two weeks.

The price of Bitcoin rose about 5% to $4,061.66 at the time of publication, hitting a market cap of $70.8 billion, as per CoinMarketCap.

READ: CryptoCann™ Report: Atari to offer blockchain-based games; former Miami Dolphin Ricky Williams launches CBD products line

The cryptoverse is wagering a few guesses as to what’s behind the Bitcoin rally.

One theory is that the Federal Reserve’s decision Wednesday to raise rates may be pushing investors toward assets with little connection to the traditional markets.

The Fed raised rates.

Long Bitcoin, Short the Bankers!

— Pomp ???? (@APompliano) December 19, 2018

Mati Greenspan, senior market analyst at social trading platform eToro, told CNBC in an email that the rally may be a result of traders closing their short positions ahead of the holidays.

"This is an extremely significant movement that may end up creating a floor for the battered down cryptocurrency," said Greenspan.

Regardless of the reason for the surge, a rising tide lifts all boats, boosting shares of Bitcoin Cash, Ethereum, Stellar, Litecoin and several others in CoinMarketCap’s top 25 list.

Notorious for its volatility, the price of Bitcoin has plummeted nearly 80% from its all-time high of $20,000 last December.


Contact Lenore Fedow at

Follow her on Twitter: @LenoreMariee

Thu, 20 Dec 2018 08:54:00 -0500
<![CDATA[Media files - Proactive Investors and Friends bring joy to the world with a special reading ]]> Wed, 19 Dec 2018 12:33:00 -0500 <![CDATA[News - CryptoCann™ Report: Bitcoin sinks to 15-month low; Maine gas station offers pot ]]> Bitcoin (BTC) sank to 15-month lows on Friday, dashing hopes of a rally signaled by current extreme oversold conditions, a report by Coindesk said.

The world’s largest cryptocurrency by market capitalization fell to $3,200 on Bitstamp -  the lowest level since September 2017.

Bitcoin was pinned in a five-day narrowing price range and seemed to show signs it might break upwards with a strong move toward the crucial resistance at $3,633.

These bullish expectations were based largely on a premise that the sellers are facing exhaustion.

READ: Crypto tax-reporting software maker NODE40 buys assets back from HashChain

Bitcoin and the wider cryptocurrency market are experiencing a terrible end to a trying year, with the price tumbling almost 50% since early November and sparking a wave of obituaries for the ailing bitcoin and crypto sector, a report by Forbes said.

The current bitcoin bear market, already labeled crypto winter for its debilitating effect on the broader market and industry, has seen more than $700 billion wiped from the total value of all cryptocurrencies so far this year, some 80% of its value since its all-time high.

Bitcoin has seen similar price percentage declines before, however, and has managed to recover from them. Now, researchers from the University of Cambridge Judge Business School have found the bitcoin industry will "likely" bounce back again.

"The speculation of the death of the market and ecosystem has been greatly exaggerated, and so it seems likely that the future expansion plans of industry participants will, at most, be delayed."


The Cann Report

Medical cannabis patients, caregivers, and advocates are gratified at the Fresno City Council’s 5-2 vote to legalize medical dispensaries, a report by High Times said.

Like others across the state, the California city had passed resolutions opting out of the state’s medical and adult-use cannabis industries.

On Thursday, members of City Council, led by Councilman Clint Olivier, approved a set of regulations allowing medical cannabis retail and establishing zoning guidelines for cultivators, distributors, and manufacturers.

The decision is a step toward recovering some of the revenue Fresno is losing due to its slow embrace of the cannabis industry.

READ: Tilray subsidiary to expand its presence in Québec via investment in cannabis producer ROSE LifeScience

A gas station and medical marijuana convenience store opened in Portland, Maine, on Thursday to provide one-stop shopping for patients looking to fuel up and later light up, a report by said.

Medical card carrying customers in Maine can now find marijuana flower, cannabis-infused products, and gas at Atlantic Farms Gas N’ Grass on Warren Avenue in Portland, the biggest city in the state and probably the first business of its kind in Maine.

The grand opening follows changes made earlier this year to the state’s medical marijuana law.

Changes to the nearly 20-year-old regulations  include allowing caregivers to buy products from other caregivers, to hire additional employees, and to open medical marijuana stores.

Contact Rene Pastor by

Fri, 14 Dec 2018 10:45:00 -0500
<![CDATA[News - CryptoCann™ Report: Michigan business comes up with marijuana as a gift; What is Bitcoin tops Google searches ]]> Revolut, a digital banking alternative that features an in-app bitcoin and cryptocurrency exchange, has received a European banking license as it seeks to expand its offerings and position itself as the “Amazon of banking,” a report by CCN said.

The London-based unicorn, which remains one of the hottest fintech startups in the UK, announced Thursday it had received permission to begin offering European customers traditional banking services alongside its current suite of products.

At first, Revolut customers in eligible jurisdictions will have the ability to sign up for direct deposit and receive deposit insurance on up to €100,000 through the European Deposit Insurance Scheme.

Later on, the company will roll out overdraft protection, as well as traditional personal and business loans.

READ: Cryptocurrency job postings are on the rise, says job site Indeed

The search term “What is Bitcoin” tops the charts in the “What is…?” category in both the UK and the US, a report by Bitcoinist said citing the latest data from Google Trends.

The phrase is attracting a lot of interest despite the fall in the bitcoin price to its lowest level in more than a year.

Cryptocurrencies have been battered as the market has entered a prolonged bear market.

The year saw around $700 billion erased off the market’s cap, with Bitcoin losing around 80% of its value.


The Cann Report

Chicago mayor Rahm Emmanuel believes legalizing recreational cannabis to address the city’s growing problems keeping up with pensions, a report by High Times said.

Citing local news sources, the report said Emanuel wants the state of Illinois to legalize recreational marijuana.

This would allow the state to establish a framework for regulating and taxing cannabis retail, which Emanuel said would bring state and local governments much-needed revenue.

Speaking at a meeting with the Chicago City Council, Emanuel said that he plans to urge state lawmakers to consider legalization.

Emanuel said that if weed became legal in Illinois, he would be able to earmark a portion of the new tax revenues to fund city pensions.

READ: Tilray adds Howard Dean and others to newly formed international advisory board

Budding entrepreneurs came up with a way around Michigan’s new recreational marijuana law, the Detroit Free Press said.

On High Road, a Boston-based online business founded and owned by Brandon Anthony, a 33-year-old Virginia native, plans to start a marijuana “gifting” service in Detroit this month.

Anthony will sell someone 21 or older a “munchie bag” filled with cookies or a muffin, candy or a T-shirt, between $55 to $120.

Along with the purchase of the bag comes a gift of marijuana, no more than the 2.5 ounces allowed under Michigan law. 

Under that law, the only way to get marijuana right now is to grow it, be a medical marijuana cardholder or have someone give it to you - not sell it.

Contact Rene Pastor by

Thu, 13 Dec 2018 10:59:00 -0500
<![CDATA[News - CryptoCann™ Report: Scientists look for steady cannabis high; Cryptocurrency exchanges in UK at low risk ]]> Cryptocurrency exchanges in the UK are at "low risk" for money laundering and terrorist financing activities, a report by Coindesk said in pointing to a report published by the Financial Action Task Force (FATF), a global anti-money laundering policymaker.

The report said that while such activities are an “emerging risk,” there is not enough evidence to suggest that they are occurring through crypto exchanges.

The regulator though has asked UK authorities to work on a plan to extend anti-money laundering and counter financing of terrorism rules in the crypto sector to tackle any potential risks.

READ: NetCents releases its first SaaS-based cryptocurrency payments processing platform

Cryptocurrency merchant bank Galaxy Digital and Block.One have led a $30 million Series A investment round in US neo-banking platform Good Money, a report by Cointelegraph said.

The investment came mostly via Galaxy and Block.One’s joint Galaxy EOS VC fund, one of several funds under the Block.One umbrella.

Good Money provides banking services and a handful of associated financial instruments to US account holders.

The Cann Report

Several companies are pouring money into research for a predictable cannabis plant that can produce a consistent high, a report by NBC News said.

These companies are hiring scientists, setting up labs and building research greenhouses that were previously used by Big Agriculture. They are hoping a product people can rely on will translate to millions of dollars in sales, the report said.

The latest forecast from Arcview Market Research in partnership with BDS Analytics concludes that US “retail flower sales are forecast to grow at a compound annual growth rate of 14.8% to reach $8.5 billion in 2022.”

The forecast added though that a growing portion of pot store customers are opting for processed cannabis concentrates that would give them a more consistent impact.

READ: Golden Leaf Holdings shares take a hit amid board shake-up

California’s cannabis business regulators have approved statewide marijuana deliveries, even in areas that ban cannabis, a report by the Marijuana Business Daily said.

The rules will not be completely finalized until approved by the Office of Administrative Law (OAL), which may not be until sometime in January.

Many believe statewide delivery - one of the most debated issues involving California’s marijuana industry - will boost sales by allowing licensed retailers and delivery businesses to reach consumers in municipalities that prohibit commercial cannabis sales.

READ: AmeriCann building million square foot sustainable cannabis facility

Contact Rene Pastor by

Tue, 11 Dec 2018 10:55:00 -0500
<![CDATA[News - CryptoCann™ Report: Bitcoin volatility spikes on price crash; 78-year old in wheelchair evicted for using medical cannabis ]]> The volatility in Bitcoin has tripled on the month as prices of the cryptocurrency crashed, a report by Cointelegraph said.

The most recent available data for December showed that BTC-USD volatility hit 5.53%, compared with 1.57% on November 9 at the start of the 30-day Volatility Index.

The volatility has been consistently rising from November 19, going from 2% to 4.53% a week later and then upwards to break above 5% on November 29.

From October 9 to November 9, Bitcoin volatility did not rise above 2.06%, ranging from around 1.5%-1.7% majority of the period, the report said.

READ: Bitcoin drops to a new low for 2018 amid market sell-off

Facebook Inc (NASDAQ:FB) has five job openings for blockchain talent at its Menlo Park, California, headquarters in the areas of data science, software engineering and marketing, a report by Coindesk said.

The company's possible plans for blockchain have not yet been disclosed. The ads on its careers pages state that the ultimate goal is to help “billions of people with access to things they don’t have now.” It further cites “equitable financial services, new ways to save, or new ways to share information” as some potential use cases for the tech.

Facebook launched its blockchain team in May. The team is headed by David Marcus, who had previously served as the company’s vice president of its Messenger app division. In June, the firm appointed a senior engineer, Evan Cheng, as its first “director of engineering, blockchain.”

The Cann Report

A 78-year old resident of Niagara Falls, New York, was evicted by his landlord for using medical marijuana, a report by High Times said.

The marshal read John Flickner his eviction order. Holding a plastic freezer bag containing his medical prescriptions, Flickner, who’s confined to a wheelchair, left his HUD-subsidized apartment.

Niagara Towers managers could have let him stay.

Instead, they opted to enforce the apartment complex’s strict drug policy and evicted Flickner for using medical cannabis to treat chronic pain from a 50-year-old spine injury.

READ: Aurora Cannabis shares light up as it enters Mexican market with exclusive supply deal

The office of legislative services, a nonpartisan bureau that assists with crafting and studying legislation, estimates that New Jersey would bring in a little over $210 million in state taxes from nearly $1.8 billion in annual marijuana sales, according to its fiscal impact study of the legal weed bill, a report by the Asbury Park Press said.

That estimate was derived from comparing New Jersey and Colorado populations in 2017, as well as Colorado marijuana sales that year. It represents less than 1% of the nearly $38 million state budget,

The legal weed bill would give New Jersey the cheapest marijuana tax in the nation, a main bone of contention between legislators and Governor Phil Murphy's office, which called for a 25% marijuana tax in its 2019 budget.

Instead, the marijuana legalization bill comes with a 12% tax. There is also a potential 2% tax that may be levied by local municipalities hosting marijuana dispensaries.

Contact Rene Pastor by

Mon, 10 Dec 2018 10:50:00 -0500
<![CDATA[News - Scandium may not be a Rare Earth but it is receiving increased focus and mentions ]]> When the film Avatar first came out, its screening coincided with the frenzy of the Rare Earth boom and we wrote a research piece on that sector and likened Rare Earths, tongue-in-cheek, to the film’s mysterious sought-after metal, Unobtainium. As history showed ultimately, Rare Earths were all too obtainable and the whole suite of metals fell out of bed and are still languishing.

At the time, some of the more ignorant of the mining space referred to Scandium as one of the Rare Earths despite it not belonging to the Lanthanide series and rarely appearing in their company in mineralisations. We note with some amusement that the latest swathe of US tariffs against Chinese metals exports targeting Rare Earths repeat the error and include Scandium in the targeted metals, despite China (to our knowledge) not being a notable producer of Scandium and certainly not an exporter of any note.

Despite this Scandium seems, in fact, to be the closest thing that we have to Unobtainium with its very scarcity being its own worst enemy. This is a situation that seems on the verge of being remedied and here, we shall discuss how and why.

The Friedland effect?

Scandium was, until 2017, one of the lesser talked about technology metals. Since last year, it has received increased focus and mention, not least because of the peripheral involvement of financier Robert Friedland in the metal. This interest came in spite of the fact that the supply situation is severely limited with literally only a few tons of product hitting the market per annum, and even that is as a by-product of the refining and processing of other metals. The applications for the element are known, particularly in aluminium alloys, solid oxide fuel cells and lighting, but it’s just that manufacturers will not tool up for the metal if they cannot be guaranteed greater (reliable) supply.

Build it and they will come?

The absence of reliable, secure, stable and long-term production has limited commercial uptake of Scandium. Despite this low level of use, Scandium offers significant benefits. The potential for substantial expansion in usage and demand clearly exists and to an extent, it is one of those “rare” metals stories where the supply could potentially generate the demand rather than the other way around. The most obvious areas where this might happen are in lighting systems, SOFCs and aluminium alloys.

In some ways, a good analogy might be Europium. Its application in colour televisions spurred a surge in REE mining (ironically at Mountain Pass) which then made the “rarer” REEs more abundant, lowering the price but, moreover, accentuating the supply which meant that new applications arose or were employed that spurred the whole evolution of the permanent magnet and laser usages of the other metals in the Lanthanide series.

It is not too difficult to imagine that greater production will, firstly, spur the master alloy applications, followed by an expansion in the SOFC demand, lighting and then “new” applications. In aircraft alone, the aluminium alloy demand might totally consume the entirety of the extra metal that nascent producers might bring to market. It is interesting to note that Bloom, the California-based SOFC manufacturer (and as such possibly the world’s major consumer of Sc), currently has an IPO underway and a word search of the prospectus yields no result for Scandium, not even in the risks section.

The Scandium space

When we first wrote on this metal, Scandium International Mining Corp (CVE:SCY) was quite clearly a lone voice in the wilderness. Since then, a number of other wannabes have appeared touting their Scandium virtues as either byproduct kickers or attempts to make unviable and unsexy projects (pardon our cynicism) into viable and sexy propositions to potential investors. In some cases, they have attracted investor attention and have had the positive effect of making the metal more high-profile than it has hitherto been. At a recent workshop at the European Space Agency, Scandium was the metal that was most mentioned with Tellurium a very distant second.

Bizarrely the Scandium space is currently being fought over like some ridge in a First World War battle in Flanders. This might be understandable if the price of the metal was raging higher but the price is one of the most obscure elements of this element. We know it is highly valued but that is a product of scarcity. There are few metals out there in which economic models and extant production plans actually guarantee a fall in the metal’s price if plans are realized, even in part.

The players in the Scandium space are concentrated in Australian properties, with two claimants that we know of, presenting properties in North America. The six are:

Clean TeQ Holdings (ASX:CLQ) - Syerston project in NSW Scandium International - Nyngan project in NSW Imperial Mining (CVE:IPG) - Crater Lake project in Quebec Platina Resources (ASX:PGM) - Owendale project in NSW Australian Mines Ltd (ASX:AUS) - Flemington project in NSW NioCorp Developments Ltd (OTCMKTS:NIOBF) - Elk Creek project in Nebraska ]]>
Fri, 07 Dec 2018 15:01:00 -0500
<![CDATA[News - Bitcoin drops to a new low for 2018 amid market sell-off ]]> Bitcoin, the digital asset synonymous with cryptocurrency, has hit a yearly low of around $3,400 as of Friday morning, with altcoins following suit.

The price of Bitcoin plummeted nearly 8% to $3,421.87 by the time of publication.

Bitcoin slipped more than 20% this week and nearly 50% this month, according to Cointelegraph’s Bitcoin Price Index.

“Bitcoin is very cheap right now. This should be the bottom of the bear market before the bounce, but it isn't / won't be. A lot of people are waking up to the crumbling economy and upcoming recession and are either one, not choosing to enter a highly speculative asset class or two, are pulling their money out of the most volatile markets, crypto included,” said Viktor Bunin, a former token designer at Brooklyn-based blockchain company ConsenSys, in an exclusive interview with Proactive Investors.

Ripple, the second-largest cryptocurrency by market cap, fell about 10% to $0.30 as of time of publication.

READ: NetCents releases its first SaaS-based cryptocurrency payments processing platform

The price of Ripple is down nearly 24% this week and down 40% in monthly losses.

Ethereum, Litecoin, EOS and Stellar were all deep in negative territory, falling by double digits.

The market cap of all cryptocurrencies totaled $107.1 billion as of this morning, a 20% drop from the nearly $136 billion market total at the beginning of the week.

Crypto Lawsuit

Cryptocurrencies are notoriously volatile, but that’s not to say there’s no rhyme or reason to the double-digit drops.

Tech development firm UnitedCorp has reportedly filed a lawsuit against Chinese mining computer manufacturer Bitmain,, the Kraken Bitcoin Exchange and early Bitcoin investor Roger Ver over the recent split of Bitcoin Cash.

WATCH: Crypto tax-reporting software maker NODE40 buys assets back from HashChain

Bitcoin Cash split off from Bitcoin’s original blockchain in August 2017 in what’s known as a hard fork, or a separation from the Bitcoin protocol.

Bitcoin Cash underwent a hard fork of its own, splitting off into Bitcoin ABC and Bitcoin SV, short for founder Satoshi’s Vision.

Interestingly, Bitcoin SV was an exception to the drop, surging 9% to $102.50.

UnitedCorp is accusing the parties of using unfair methods to manipulate the Bitcoin Cash network to their benefit.

“UnitedCorp believes that the defendants colluded to effectively hijack the Bitcoin Cash network after the November 15, 2018 scheduled software update with the intent of centralizing the network — all in violation of the accepted standards and protocols associated with Bitcoin since its inception,” states the suit filed in the US District Court for the Southern District of Florida.

The Bitcoin ETF Dream Dashed

The US Securities and Exchange Commission has once again crushed the dream of a Bitcoin exchange-traded fund, which may be a possible explanation for the drop.

The SEC has postponed its decision on an application for a Bitcoin ETF submitted by VanEck and Solid X until February, following a previous postponement.

“Don’t hold your breath. I do caution people to not live or die on when a crypto or Bitcoin ETF gets approved. You all know that I am working on trying to convince my colleagues to have a bit more of an open mind when it comes to [crypto]. I am not as charming as some other people,” said SEC Commissioner Hester Peirce.

The SEC did not give an exact time frame for the potential approval of an ETF, with Peirce saying it could see approval tomorrow or in 10 years.

--Updated to include commentary and recent price movement


Contact Lenore Fedow at

Follow her on Twitter: @LenoreMariee

Fri, 07 Dec 2018 08:38:00 -0500
<![CDATA[News - Catenae Innovation signs first deal for platform using its blockchain technology ]]> Catenae Innovation PLC on Thursday said it has signed a deal with STM Security UK - its first contract for a solution using its blockchain technology, sending its shares higher.

The digital media and technology company said it would supply STM with OnGuard Plus, a business management solution specifically developed for the security industry.

READ: NetCents Technology draws nomination for blockchain company of year award

The integration of Catenae’s Sequestrum distributed ledger technology provides organisations with the ability to store critical and regulatory reports in an immutable form within the Sequestrum repository, providing auditable proof of both the existence of the report as well as its original content.

Revenue is generated via an annual ‘in advance’ licence fee as well as a transaction fee on a ‘per report’ basis.

Catenae also said it had recently completed final testing of Sequestrum, its digital repository running on the hyper ledger blockchain platform. This recent technical development opens up the opportunity for Sequestrum to be run on the client’s choice of Blockchain platform, significantly broadening its potential application, the company said.

The blockchain firm also announced the launch of its management and inspection platform – OnSite, a product developed specifically for the construction industry. The product provides the ability for companies to manage and schedule their workforce and provides a universal inspection and reporting tool that can be adapted to meet the regulatory reporting standards for this industry.

Shares in Catenae were 16.2% up at 0.12p in early afternoon trade.

Thu, 06 Dec 2018 13:45:00 -0500
<![CDATA[News - Lyft races towards IPO with confidential SEC filing ]]> Uber’s closest rival Lyft disclosed Thursday it has confidentially filed a draft registration statement with the Securities and Exchange Commission related to its proposed initial public offering.

The move has been expected and is a key step for the closely held company toward becoming a publicly traded company.

IPO Roundup: Uber and Lyft race towards IPOs as bank s line up

Lyft selected underwriters, including JPMorgan Chase & Co, Credit Suisse Group AG and Jefferies Group LLC, for the offering, which is expected in the first half of next year, The Wall Street Journal reported in October.

The Journal said Lyft’s valuation is expected to top the $15.1 billion it was valued at earlier this year, though private valuations can change until the company prices its IPO.

Lyft’s decision to take the big step toward an IPO comes as rival Uber is also weighing an early 2019 listing and recently received proposals from banks valuing it at as much as $120 billion.

Lyft, which is part of the sharing economy, makes money by taking a commission on rides booked through its app.

It did not specify how much it's seeking to raise or how much it believes it's worth.

The San Francisco-based company reported revenue of $563 million, up 88% compared with the year-earlier period, the Journal has reported. It lost $254 million in the quarter, versus a $195 million loss last year.


Contact Uttara Choudhury at

Follow her on Twitter: @UttaraProactive 

Thu, 06 Dec 2018 08:41:00 -0500
<![CDATA[News - Nightstar Therapeutics deserves a spot on your watchlist if you are an aggressive biotech investor ]]> The past two months have been brutal for investors, especially for those focused on small- and micro-cap stocks. And the pain is even more pronounced for investors focused on biotech stocks.

Now, biotech stocks aren’t for everyone. While the potential upside can be spectacular, biotech investors must be prepared for frequent bouts of extreme volatility, and if the drug compound a company is working on fails to meet expectations, bankruptcy can be a real possibility.

However, there are steps we can take to minimize our risks and de-risk potential investments. Sticking with companies that are well funded, for example, is one of the easiest ways to ensure the company we’re invested in won’t run out of money mid-way through their FDA trials.

Another way we can reduce our risk is by identifying investment prospects and getting involved during periods of weakness. Like right now, when many stocks are trading significantly beneath their 52-week highs.

An Opportunity in Gene Therapy

UK-based Nightstar Therapeutics (NASDAQ:NITE) is a $500 million clinical-stage gene therapy company focused on developing and commercializing a pipeline of new and potentially curative, one-time treatments for patients suffering from rare inherited retinal diseases.

The company is currently working to develop RSR-REPI for the treatment of Choroideremia, NSR-RPGR for the treatment of X-linked Retinitis Pigmentosa, NSR-ABCA4 for the treatment of Stargardt Disease, NSR-BEST1 for the treatment of Best Disease, and NSR-CNTF, NSR-OPN4, and NSR-RHO for the treatment of Retinitis Pigmentosa.

Now, rather than give you a brief overview of Nightstar’s various programs, I want to focus on the company’s lead product candidate for the treatment of Choroideremia.

NSR-REP1 for the Treatment of Choroideremia

The company’s lead product candidate is NSR-REP1 for the treatment of Choroideremia (CHM). And while you may be unfamiliar with Choroideremia, I assure you it’s a tortuous nightmare for the one in 50,000 individuals afflicted with the disease.

CHM is caused by a genetic defect in a single gene located on the X-chromosome, so while females can carry the defective gene, most CHM sufferers are males. And women who do experience CHM symptoms tend to develop only patchy vision loss or night blindness.

Without getting too deep into the weeds, Choroideremia affects the retina and is caused by mutations in the CHM gene which, when operating correctly, produces the protein REP1 that removes waste from retinal cells.

Failure to remove waste from the retinal cells results in the retina deteriorating, and over time, all vision is lost. You become blind.

Now, what makes Choroideremia so devastating is that there are no currently approved or effective treatments, and the effects of the disease manifest at an early age.

Boys as young as five or six begin to experience night blindness, and by the time these boys reach their early 20s, they’ve likely lost their peripheral field of vision.

But night blindness and a loss of peripheral vision are only the beginning.

As CHM sufferers reach their mid to late 20s, peripheral vision is a thing of the past, and all that remains is a tiny area of “tunnel” vision. To put this into perspective, make a fist with your hand, but leave a small opening so you can look through as though it were a pirate telescope. What you see when you’re peering through your fist is what CHM sufferers live with day-in and day-out as they approach their thirties.

Now, while the rate of vision loss generally slows after CHM sufferers develop tunnel vision, the disease is still slowly stealing one’s ability to see. And by the time a patient reaches his 50s or 60s, complete blindness has likely set in.

Relief on the Horizon

On March 5, 2018, Nightstar entered into Phase 3 clinical development (the STAR trial) to study the safety and efficacy of NSR-REP1 in patients with CHM. By the end of Q2 2019, Nightstar’s goal is to enroll 140 patients across 18 clinical sites in the U.S., Europe, Canada, and South America. One-year follow-up data is expected during 2020.

A final point that’s worth noting regarding NSR-REP1 is that both the FDA and European Medicines Agency have granted Nightstar the orphan drug designation. Additionally, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for NSR-REP1 in mid-June 2018.

The bottom line is Nightstar is making significant progress with its treatment for Choroideremia, and the company’s efforts have not gone unnoticed by regulators. And while we can all get behind a company that is actively developing drugs to for illnesses that currently have no treatment options, as investors, we also appreciate the profit potential associated with being first to market with a new drug.

Well-Funded and Investing in the Future

Like most clinical-stage biotechnology companies, Nightstar’s expenses are on the rise while no meaningful revenue is being generated. But this is to be expected and should not necessarily be viewed as a red flag.

When Nightstar reported its Q3 2018 financial results on November 13, the company reported a near-doubling of its research and development expenses on a year-on-year basis. But this was to be expected as the company is actively pressing forward with the development of NSR-REP1 and NSR-RPGR for the treatment of X-linked retinitis pigmentosa.

Now, given Nightstar’s increased pace of investment into their two primary drug candidates, it goes without saying that investors should have one eye on the company’s cash balance.

At the end of Q3 2018, the company reported a cash balance of $100.8 million, down $28.6 million from Q3 2017. However, on October 2, 2018, just two days into Q4, the company completed an underwritten public offering of 4.6 million shares and took in approximately $77.1 million.

So, while $100 million in cash is great for a clinical-stage biotechnology company and easily could have supported the company’s programs well beyond 2019, the additional cash infusion provides Nightstar with ample reserves to finish their research and further de-risks the stock for current and potential investors.

A Bumpy but Promising Future

Investors dream of buying a stock and watching it tick higher month after month. But that’s rarely the way things play out ... especially when it comes to small-cap clinical-stage biotech stocks.

Nightstar got off to a slow start following its September 28, 2017, IPO, but that’s likely because the company is based in the UK and wasn’t well known among US-based biotech investors. However, once the company received RMAT designation for NSR-REP1 in mid-June 2018, investors woke up and started paying attention.

The stock nearly doubled between mid-June and late-September, but that bullish momentum faded in late-September and thanks to market-wide de-risking, especially when it comes to more volatile small-cap stocks, the stock currently trades more than 45% beneath its September 20 high.

Like every industry, investor interest in biotech stocks ebbs and flows. However, if you’re an aggressive biotech investor that appreciates the promise that gene therapy holds, Nightstar Therapeutics deserves a spot on your watchlist. Especially while it’s trading so far beneath its 52-week high.

Wed, 21 Nov 2018 12:38:00 -0500
<![CDATA[News - Cryptocurrency job postings are on the rise, says job site Indeed ]]> The cryptocurrency market is having a volatile year, but there are still crypto jobs to be filled.

The number of crypto-related job postings increased by more than 25% compared with October 2017.

Whether job seekers want these jobs or not is another story.

Searches for jobs involving bitcoin, blockchain and cryptocurrency dropped by about 3% this October compared with last October, according to data provided to Coindesk by job site Indeed.

“While over the last few years Indeed saw a steady rise in job seeker interest for roles related to cryptocurrency, our data shows that job searches for these roles really picked up around the time when the cost of bitcoin was at its highest. Since then job seeker interest has gone down, but still remains strong,” Raj Mukherjee, Indeed’s senior vice president of product, told CoinDesk.

Job seeker and employer interest were much higher in October 2017. Job seeker interest rose by more than 481% last October, while employer interest was up by 325%.


Contact Lenore Fedow at

Follow her on Twitter: @LenoreMariee

Fri, 16 Nov 2018 13:47:00 -0500
<![CDATA[News - Tech innovators and disruptors shine at Dawson James Securities’ Small-Cap Conference ]]> Last week, Dawson James Securities brought together some of the most exciting names in tech at its fourth annual Small-Cap Conference in Jupiter, Florida. Among the standouts attending were several companies that Proactive Investors identified as innovators and disruptors.

Payment Data Systems Inc (NASDAQ:PYDS) is an electronic-payment processor that Senior Vice President of Corporate and Prepaid Development Houston Frost says is “in it to win.”

The San Antonio, Texas-based company is building on the innovations of payment processors like Square Inc (NYSE:SQ) and Stripe to change the way merchants and consumers make electronic payments.  

On the business side, PDS streamlines the payment process between merchants and banks and lowers costs for the merchants. The company offers fully integrated payments, partnerships with Software as a Service (SaaS) companies, as well as card issuance.

“The technological innovation that we’re pushing is to partner with SaaS companies and instead of online registration, all the data is coming to us from the back end,” explained Chief Revenue Officer Vaden Landers.

Because the company's processing platform is integrated with SaaS products, it is introduced to all the corresponding SaaS company's customers. "We partner and integrate with an SaaS company, who in turn offers our service to all of its customers through the integration," explained Frost. That gives PDS the ability to offer its solutions to professional groups, such as doctors and other health care professionals, as well as merchants, in large number rather than one by one.

On the consumer side, PDS has created the Akimbo card for individuals, a reloadable prepaid card to manage household finances. This, says Frost, is an exciting part of the company.

“Instead of being a just ‘me too’ payments type company this is what we’re really doing differently,” Frost added.

Growth has accelerated, as the company nearly doubled the number of employees in just the past year to more than 40.

Innovating on the big stage

LiveXLive Media Inc (NASDAQ:LIVX) is not unaccustomed to the spotlight. CEO Robert Ellin tells Proactive Investors that the Beverly Hills-based company has built the largest live streaming network in the world, over which it streams more than 20 of the biggest live music festivals.

“I took the playbill from ESPN and applied it to music to create the next generation in TV,” Ellin told Proactive. “There’s been no one in this lane for 25 years, so since MTV there’s been a missing link in pop culture.”

READ: LiveXLive Media's Slacker Radio can now be streamed via Amazon's Alexa

LiveXLive streams 27 of largest music festivals in the world including EDC, the biggest dance festival, Rock in Rio, and the venerable Montreaux Jazz Festival.

“I can humbly say we’re the thought-leader in the world in live music,” Ellin said.

Last year the company acquired Slacker Radio for $33 million and recently partnered with powerhouse convert promoter Live Nation Entertainment Inc (NYSE:LYV).

A turnaround in the making

Besides innovators and disruptors, there's a turnaround story in WidePoint Corp (NYSE:WYY), which ended its third quarter revenue positive, reversing several years of losses as it adds to its cash position and returns to profitability since CEO Jin Kang took control in July 2017.

At the core of its future, Kang says, is the integration of its three main businesses: TM2 telecom management, identity authentication (IDM) and bill presentment and analytics.

WidePoint provides Trusted Mobile Management, or TM2, to companies and government agencies with more than a thousand mobile devices to track and manage.  So, every aspect of telecom management, from set-up to turning off access when devices are lost, is handled by WidePoint, as well as identity management tools that allow clients to track and secure all mobile phones issued to staff. 

“It’s not enough that you can manage these devices and secure them using identity certificates, you also need to have visibility and analytics,” Kang explained.

To that end, WidePoint can service and enforce policy for companies for as little as $40 per device, Kang said. And on the back end, WidePoint provides data and analytics to see how much data are being used by organizations and how, as well providing consumer-level data for telecom customers of providers like Verizon Inc (NYSE:VZ).

Customers include the Department of Homeland Security -- capturing $400 million of the agency's $600 million annual spend -- as well as companies such as Sunoco LP (NYSE:SUN) and America Airlines Group (NUSE:AAL).

Growth that makes sense

Among the disruptors is Focus Universal Inc (OTCMKTS:FCUV), whose founder Desheng Wang has flipped the design process for environmental sensors on its head. The Walnut, California, company makes customizable, modular sensors that connect to any smartphone.

Focus’s sensors replace cumbersome legacy units that only have a single purpose but represent a $2 billion market that serves the agricultural industry.

The company offers 500 modular sensors that measure anything from CO2 to radiation to humidity to light. The sensors can be daisy-chained in any combination to a smartphone and the resulting data saved via the cloud.

Focus International got a US patent earlier this year for a system that provides a universal solution for a sensor communicating with a gateway to a monitoring control from a smartphone.

The company has raised $10.6 million so far and applied to uplist its shares Nasdaq from the OTC Markets.

When asked by Proactive if the platform also lends itself to use with the cannabis-growing industry, Shane Vultee of Veyo Partners, which is acting as an advisor, was frank: “Obviously being in California, it’s a very easy transition to make.”

Wed, 07 Nov 2018 14:15:00 -0500
<![CDATA[News - Michigan, Missouri and Utah vote ‘yes’ on marijuana, but North Dakota’s hopes go up in smoke ]]> Voters in four states headed to the ballot box Tuesday to vote on marijuana proposals with three scoring a victory.

A recent Gallup poll found that 64% of Americans were in support of marijuana legalization.


Michigan voted in favor of Proposal 18-1, legalizing recreational use in the state for those 21 years of age or older.

The proposal will also legalize commercial sales of cannabis through state-licensed retailers, subject to a 10% tax.

READ: Weekend Unlimited upbeat on tenant Orchard Heights' proof-of-concept cannabis harvest

Michigan residents will be permitted to have up to 10 ounces of cannabis at home, but amounts over 2.5 ounces will need to be stored in a locked container. Edibles have also been given the green light.

Residents will be allowed to grow up to 12 marijuana plants for personal use.

The use of medical marijuana has been legal in the state since 2008.

North Dakota

North Dakota voters struck down a proposal to legalize recreational use.

The Marijuana Legalization and Automatic Expungement Initiative would have legalized the recreational use of marijuana for people 21 years of age or older.

The passage of the proposal also would have created a system to help expunge the records of those with marijuana-related convictions.

North Dakota legalized medical marijuana for patients with serious medical conditions back in 2016.


It was another victory for cannabis advocates in Missouri, but not all three marijuana-related proposals passed.

Michigan voted in favor of Amendment 2, which allows doctors to prescribe medical cannabis for certain conditions and also patients using medical cannabis to grow their own plants or get their supply from a dispensary.

READ: CryptoCann™ Report: Apple reportedly blocks popular crypto podcast; Harvard astronomers publish paper on joint-shaped space object

The state constitutional amendment passed by a margin of 66% to 34%, according to a Forbes report.

"Thanks to the unflagging efforts of patients and advocates, Missourians who could benefit from medical marijuana will soon be able to use it without fear of being treated like criminals," said Matthew Schweich, deputy director of the Marijuana Policy Project, to Forbes.

The state will impose a 4% retail tax on medical cannabis sales, funneling the revenue to services for military veterans.

The first proposal that would have removed state restrictions on the growth, possession and sale of medical cannabis by licensed facilities and put a 2% tax on retail sales failed.

The third proposal that would have put a 15% tax on retail sales, funneling the money towards a state research institute that would focus on cannabis-based cancer treatments, failed as well.


It was another win for medical marijuana in Utah.

Utah voted in favor of a proposal to legalize medical marijuana for people with certain conditions.

"Even in socially conservative states like Utah, most voters recognize marijuana has significant medical value, and they believe it should be available to patients who could benefit from it," said Schweich in a Forbes interview.

Doctors will have the ability to recommend that qualifying patients receive a medical marijuana card.

Over a 14-day period, medical marijuana patients can choose to buy 2 ounces of cannabis or a marijuana-based product with more than 10 grams of THC.

Recreational marijuana use has recently been legalized in Vermont and the Northern Mariana Islands in the Pacific while medical use has been approved by voters in Oklahoma.


Contact Lenore Fedow at

Follow her on Twitter: @LenoreMariee

Wed, 07 Nov 2018 08:49:00 -0500
<![CDATA[News - Marijuana and the Midterms: Legal cannabis could be headed to these four states ]]> US cannabis connoisseurs, as well as patients seeking marijuana-based treatments, were green with jealousy after northern neighbor Canada legalized cannabis last month.

But don’t despair — voters in a handful of states will be able to vote on marijuana legalization in Tuesday’s Midterm election.

READ: Weekend Unlimited upbeat on tenant Orchard Heights' proof-of-concept cannabis harvest

Investors may want to keep an eye on the results considering the legal marijuana market is expected to reach $24.5 billion in sales by 2021, according to a report by Arcview Market Research and BDS Analytics.

The North American Marijuana Index, which tracks the leading cannabis stocks in the US and Canada, was up about 2% Tuesday afternoon ahead of the vote.


In Michigan, voters will have the opportunity to vote on Proposal 18-1, a bill to legalize the use of recreational marijuana for people 21 years or age or older.

Michigan residents can have up to 10 ounces of cannabis at home, but amounts over 2.5 ounces would need to be secured in locked containers.

The bill would also legalize commercial sales of cannabis through state-licensed retailers, subject to a 10% tax.

Edibles would also be allowed under the proposal as well as growing up to 12 marijuana plants for person consumption.

The proposal would also convert a number of crimes to civil infractions.

The use of medical marijuana is already legal in the state.

North Dakota

Recreational use is also on the ballot in the state of North Dakota.

The Marijuana Legalization and Automatic Expungement Initiative would legalize the recreational use of marijuana for people 21 years of age or older.

READ: CryptoCann™ Report: Apple reportedly blocks popular crypto podcast; Harvard astronomers publish paper on joint-shaped space object

The initiative would also create a system to help expunge the records of those with marijuana-related convictions.

North Dakota legalized medical marijuana for patients with serious medical conditions back in 2016.


Things get a little technical in Missouri as voters are asked to decide on three medical marijuana proposals.

The first proposal would remove state restrictions on the growth, possession and sale of medical cannabis by licensed facilities and put a 2% tax on retail sales.

The second proposal allows doctors to prescribe medical cannabis for certain conditions and also patients using medical cannabis to grow their own plants or get their supply from a dispensary.

The third proposal would put a 15% tax on retail sales, funneling the money towards a state research institute that would focus on cannabis-based cancer treatments.


Utah voters will also decide on a medical marijuana proposal.

The proposal would legalize medical marijuana for people with certain conditions. Doctors would have the ability to recommend that qualifying patients receive a medical marijuana card.

Over a 14-day period, medical marijuana patients can choose to buy 2 ounces of cannabis or a marijuana-based product with more than 10 grams of THC.

Recreational marijuana use has recently been legalized in Vermont and the Northern Mariana Islands while medical use has been approved by voters in Oklahoma.

A recent Gallup poll found that 64% of Americans were in support of marijuana legalization.


Contact Lenore Fedow at

Follow her on Twitter: @LenoreMariee

Tue, 06 Nov 2018 14:05:00 -0500
<![CDATA[News - Kaiser Aluminum beats Street on 3Q and 9-month results; offers rosy 2019 outlook ]]> Kaiser Aluminum Corp (NASDAQ:KALU) reported beats in both third-quarter and nine-month earnings while predicting the company should perform even better going into 2019.

The Foothill Ranch, California, company said net sales for the first nine months of 2018 were $1.2 billion, up approximately 15% from the $1.0 billion in the prior year, reflecting 4% higher shipments and a 10% increase in average selling price per pound. The increase in average selling price reflected a 22% increase in contained metal costs per pound while value added revenue per pound was comparable to the prior year period.

Net sales for the third quarter 2018 were $393 million, an increase of approximately 18% from the $333 million in the prior year period, reflecting 6% higher shipments and a 12% increase in average selling price per pound. The increase in average selling price reflected an approximately 23% increase in underlying contained metal cost and a 3% increase in value added revenue per pound. The consensus for the quarter was $389.3 million.

“As we begin to look to 2019, we expect demand across our end markets to be strong. Although sales margins have improved, they remain at historical lows. We will continue to monitor market conditions to determine timing for further price increases to restore our sales margins to a level more reflective of the strong overall demand climate," said Jack Hockema, the chairman and CEO of Kaiser.

“For the full year 2018, we continue to anticipate mid-single-digit growth in shipments and value added revenue with adjusted EBITDA margin in the mid-20 percent range. We expect continued underlying demand strength in the fourth quarter 2018 with moderating destocking in the aerospace supply chain and normal seasonality in industrial demand," he said.

READ: IBC and NioCorp complete initial casting campaign for aluminum-scandium alloys

The official said "strong operating leverage and improved sales margins more than offset the temporary impact of tariffs on our internal cross-border shipments" referring to the tariffs slapped on metal imports by the Trump administration

"We are awaiting government approvals of certain countermeasures that we have initiated to eliminate nearly all our cross-border tariff costs and retroactively recover costs incurred. Although the tariffs have negatively impacted short-term results, we continue to anticipate that the long-term impact to us will be neutral to slightly positive should the tariffs remain in place,” he added.

Kaiser Aluminum is a producer of semi-fabricated specialty aluminum products.

Reporting by Rene Pastor, contactable on

Wed, 17 Oct 2018 16:58:00 -0400
<![CDATA[News - New crowdsource App HeyBryan takes the legwork out of home repairs ]]> HeyBryan is a new crowdsourcing app set to launch this fall that takes the hassle out of those all-important home repair jobs.

It is being backed by the cable TV group  HGTV’s award-winning star Bryan Baeumler, who appears in hit Canadian shows such as House of Bryan, Bryan Inc and Disaster DIY.

The HeyBryan app is set to launch soon for Android and iPhone.

"We decided to create this app because, like many entrepreneurs - we identified a problem that we wanted to solve, both for ourselves and for others," said Lance Montgomery, the president and CEO and co-founder of  HeyBryan Inc.

"It was always difficult to find the right people who you can trust to take care of things around the house, from small repairs to cleaning and other tasks.

“We thought it would be great if people could simply ask: HeyBryan - do you know a painter? and that's where the name of the app came from.”

The home improvement market in Canada reached an eye-watering $47.9 billion in 2017.

Available services on the app include general handyman services, furniture assembly, cleaning, electrical, plumbing and painting.

Homeowners can review and rate home service providers directly through the app, and those who consistently earn high ratings and positive reviews will be HeyBryan certified.

TV show host Baeumler said: "Home repair and related services are areas that haven’t seen tremendous innovation the same way that industries like food services have.

"And this is a huge problem, because unlike having the wrong pizza delivered - the wrong service provider can cause irreparable damage to your home or other possessions," he said.

Mon, 15 Oct 2018 06:29:00 -0400
<![CDATA[Media files - Small-Cap Snapshot: Obalon Therapeutics pops after FDA approves gastric balloons ]]> Wed, 26 Sep 2018 17:12:00 -0400 <![CDATA[Media files - CryptoCann™ Report: Celebrity Winklevoss twins target UK market ]]> Mon, 24 Sep 2018 14:45:00 -0400 <![CDATA[Media files - Small-Cap Snapshot: Intrexon edges up on medical cannabis developments ]]> Mon, 24 Sep 2018 14:29:00 -0400